Trading exchangesNASDAQ

Products 1 to 10 of 69

ActoBiotics: AG013 (Oral Mucositis) by Actobio Therapeutics
Biotech components: Bacteria
Business models: B2C
Country of production: N/A
Country of distribution: N/A
Intended consumer: N/A
Date added: 2019/09/12 15:12 (1 year ago)
Date last modified: 2019/09/12 15:12 (1 year ago)
Known funding amount: N/A
Funding types: Government + Shareholder Investment
Industry: Medical
Market status: Under Development
Organization type(s): Private Company
Product categories: Personal Care (Topical) + Medicine
Production process: N/A
Source: Web search
Trading symbol: XON (NASDAQ)
Value chain stage: Finished Product
ActoBiotics: AG017 (Celiac Disease) by Actobio Therapeutics
Biotech components: Bacteria
Business models: B2C
Country of production: N/A
Country of distribution: N/A
Intended consumer: N/A
Date added: 2019/09/12 15:12 (1 year ago)
Date last modified: 2019/09/16 16:28 (1 year ago)
Known funding amount: N/A
Funding types: Private Funding + Shareholder Investment
Industry: Health + Medical
Market status: Early Stage Concept
Organization type(s): Private Company
Product categories: Personal Care (Ingested)
Production process: N/A
Source: Web search
Trading symbol: XON (NASDAQ)
Value chain stage: Finished Product
ActoBiotics: AG018 (Rhinosinusitus) by Actobio Therapeutics
Biotech components: Bacteria
Business models: B2C
Country of production: N/A
Country of distribution: N/A
Intended consumer: N/A
Date added: 2019/09/12 15:12 (1 year ago)
Date last modified: 2019/09/12 15:12 (1 year ago)
Known funding amount: N/A
Funding types: Private Funding + Shareholder Investment
Industry: Medical
Market status: Under Development
Organization type(s): Private Company
Product categories: Personal Care (Topical)
Production process: N/A
Source: Web search
Trading symbol: XON (NASDAQ)
Value chain stage: Finished Product
ActoBiotics: AG019 (Type 1 Diabetes) by Actobio Therapeutics
Biotech components: Bacteria
Business models: B2C
Country of production: N/A
Country of distribution: N/A
Intended consumer: N/A
Date added: 2019/09/12 15:12 (1 year ago)
Date last modified: 2019/09/12 15:12 (1 year ago)
Known funding amount: N/A
Funding types: Private Funding + Shareholder Investment
Industry: Medical
Market status: Under Development
Organization type(s): Private Company
Product categories: Medical Treatment + Medicine
Production process: N/A
Source: Web search
Trading symbol: XON (NASDAQ)
Value chain stage: Finished Product
Biotech components: Bacteria
Business models: B2C
Country of production: N/A
Country of distribution: N/A
Intended consumer: N/A
Date added: 2019/09/12 15:12 (1 year ago)
Date last modified: 2019/09/12 15:12 (1 year ago)
Known funding amount: N/A
Funding types: Private Funding + Shareholder Investment
Industry: Medical
Market status: Early Stage Concept
Organization type(s): Private Company
Product categories: Personal Care (Topical)
Production process: N/A
Source: Web search
Trading symbol: XON (NASDAQ)
Value chain stage: Finished Product
AquAdvantage Salmon (#1) by AquaBounty
Biotech components: Animal
Business models: B2C
Country of production: USA + Canada
Country of distribution: USA + Canada
Intended consumer: Commercial
Date added: 2018/08/30 11:49 (2 years ago)
Date last modified: 2018/08/30 11:49 (2 years ago)
Known funding amount: 28,300,000 USD
Funding types: Private Funding + Venture Capital
Industry: Food & Agriculture
Market status: On the market
Organization type(s): Private Company
Product categories: Food
Production process: Open Release
Source: Web search
Trading symbol: AQB (NASDAQ)
Value chain stage: Finished Product
AquAdvantage Salmon (#2) by AquaBounty
Biotech components: Animal
Business models: B2C
Country of production: USA
Country of distribution: USA + Canada
Intended consumer: Consumer
Date added: 2018/08/30 11:49 (2 years ago)
Date last modified: 2018/09/06 10:13 (2 years ago)
Known funding amount: 38,000,000 USD
Funding types: Shareholder Investment
Industry: Food & Agriculture
Market status: On the market
Organization type(s): Public Company
Product categories: Food
Production process: Open Release
Source: NASEM Database
Trading symbol: AQB (NASDAQ)
Value chain stage: Finished Product
Artemisinic Acid by Amyris
Biotech components: Probiotic
Business models: B2B
Country of production: USA
Country of distribution: USA + Africa + France
Intended consumer: Commercial + Government
Date added: 2018/08/30 11:49 (2 years ago)
Date last modified: 2018/08/30 11:49 (2 years ago)
Known funding amount: 471,900,000 USD
Funding types: Shareholder Investment
Industry: Health
Market status: On the market
Organization type(s): Public Company
Product categories: Chemical
Production process: Closed Production
Source: SynBio Database
Trading symbol: AMRS (NASDAQ)
Value chain stage: Input
Biopolymer I6001 by Yield10 Bioscience + Metabolix
Biotech components: Bacteria + Plant
Business models: B2B
Country of production: USA
Country of distribution: USA + Europe
Intended consumer: Commercial
Date added: 2018/08/30 11:49 (2 years ago)
Date last modified: 2018/10/01 09:56 (2 years ago)
Known funding amount: 41,800,000 USD
Funding types: Shareholder Investment
Industry: Industrial
Market status: On the market
Organization type(s): Public Company
Product categories: Chemical
Production process: Closed Production
Source: SynBio Database
Trading symbol: YTEN (NASDAQ)
Value chain stage: Input
Biopolymer I6003rp by Yield10 Bioscience + Metabolix
Biotech components: Bacteria + Plant
Business models: B2B
Country of production: USA
Country of distribution: USA + Europe
Intended consumer: Commercial
Date added: 2018/08/30 11:49 (2 years ago)
Date last modified: 2018/10/01 09:56 (2 years ago)
Known funding amount: 41,800,000 USD
Funding types: Shareholder Investment
Industry: Industrial
Market status: On the market
Organization type(s): Public Company
Product categories: Chemical
Production process: Closed Production
Source: SynBio Database
Trading symbol: YTEN (NASDAQ)
Value chain stage: Input